1. Medtech Insight
  2. >>Archive

CLIA waiver status for Osteomark NTx PoC (point-of-care) test:

The FDA has extended its clearance for Ostex International's Osteomark NTx Point-of-Care device to make it available in virtually all physicians' offices. The test, which measures cross-linked N-telopeptides of type I collagen (NTx), a marker of bone resorption, is used to monitor the effect of treatment in osteoporosis patients. It was originally approved in the US in 1999, but the FDA has now granted it Rx Home-Use clearance and CLIA waiver status. The new, wider approval will also mean the test can be distributed through pharmacies with a physician's script. The Seattle, Washington company is currently constructing a new manufacturing facility for the test, due for completion in the fourth quarter of this year.

The FDA has extended its clearance for Ostex International's Osteomark NTx Point-of-Care device to make it available in virtually all physicians' offices. The test, which measures cross-linked N-telopeptides of type I collagen (NTx), a marker of bone resorption, is used to monitor the effect of treatment in osteoporosis patients. It was originally approved in the US in 1999, but the FDA has now granted it Rx Home-Use clearance and CLIA waiver status. The new, wider approval will also mean the test can be distributed through pharmacies with a physician's script. The Seattle, Washington company is currently constructing a new manufacturing facility for the test, due for completion in the fourth quarter of this year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

J&J MedTech Launches KINCISE 2 Surgical Automated System In US

 
• By Natasha Barrow

The KINCISE 2 Surgical Automated System aims to “reduce the physical burden on surgeons compared to manual impaction in primary and revision hip and revision knee replacement procedures,” said J&J MedTech.

Johnson & Johnson MedTech: How To Scale Digital Solutions

 
• By Natasha Barrow

J&J's EMEA head of digital solutions, Julia Fishman, talks about the major hurdles in scaling digital innovation, tips for clinical adoption and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

Quest Diagnostics Minimizes China Tariff Risk With Less Than 1% Supply Chain Exposure

 
• By Shubham Singh

Quest reaffirmed its full-year guidance despite macroeconomic concerns and tariff uncertainty. Revenues are expected between $10.7bn and $10.85bn. Adjusted earnings per share (EPS) is estimated in the $9.55 to $9.80 range for the full year, with EPS between $8.62 and $8.87.